STOCK TITAN
  1. Home
  2. Sec-filings
  3. FEED
  4. [Form 4] ENvue Medical, Inc. Insider Trading Activity

Bank of America entities sell ENvue Medical (FEED) shares near $3.05

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Bank of America Corp, BOFA Securities and Bank of America NA jointly reported a series of open-market sales of ENvue Medical, Inc. (FEED) common stock on 02/02/2026. The trades were executed at prices generally around $3.04–$3.07 per share, each reducing the reported indirect position.

After these transactions, the reporting persons show 231,138 shares of ENvue Medical common stock beneficially owned on an indirect basis. The footnotes explain that Bank of America’s interest is indirect through its subsidiaries and include disclaimers about group status and greater-than-10% beneficial ownership.

Positive

  • None.

Negative

  • None.
Insider BANK OF AMERICA CORP /DE/, BOFA SECURITIES, INC., BANK OF AMERICA NA
Role 10% Owner | 10% Owner | 10% Owner
Sold 2,918 shs ($9K)
Type Security Shares Price Value
Sale Common Stock 100 $3.05 $305.00
Sale Common Stock 10 $3.05 $30.50
Sale Common Stock 4 $3.05 $12.20
Sale Common Stock 4 $3.05 $12.20
Sale Common Stock 100 $3.04 $304.00
Sale Common Stock 200 $3.06 $612.00
Sale Common Stock 500 $3.05 $2K
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 18 $3.05 $54.90
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 100 $3.05 $305.00
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 100 $3.05 $305.00
Sale Common Stock 100 $3.05 $305.00
Sale Common Stock 183 $3.05 $558.15
Sale Common Stock 2 $3.05 $6.10
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 417 $3.05 $1K
Sale Common Stock 98 $3.05 $298.90
Sale Common Stock 82 $3.05 $250.10
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 100 $3.06 $306.00
Sale Common Stock 50 $3.05 $152.50
Sale Common Stock 100 $3.07 $307.00
Sale Common Stock 90 $3.05 $274.50
Sale Common Stock 10 $3.05 $30.50
Sale Common Stock 100 $3.07 $307.00
Sale Common Stock 100 $3.05 $305.00
Holdings After Transaction: Common Stock — 233,956 shares (Indirect, See Footnotes)
Footnotes (1)
  1. This statement is jointly filed by Bank of America, BANA and BOFAS. Bank of America holds an indirect interest in the securities listed in Table I ("the Securities") by virtue of its indirect ownership of its subsidiaries, BANA and BOFAS. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of (ii) a member of any group with respect to the Issuer or any securities of the Issuer. Without conceding its status as a greater than 10% beneficial owner or that the reported transactions are subject to disclosure under Section 16(a) of the Exchange Act or short-swing profit recovery under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that the Reporting Persons were greater than 10% beneficial owners and the transactions were subject to Section 16(b) has been or will be remitted to the Issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BANK OF AMERICA CORP /DE/
(Last) (First) (Middle)
BANK OF AMERICA CORPORATE CENTER
100 N TRYON ST
(Street)
CHARLOTTE NC 28255
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ENvue Medical, Inc. [ FEED ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/02/2026 S 100 D $3.05 233,956 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 10 D $3.05 233,946 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 4 D $3.05 233,942 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 4 D $3.05 233,938 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.04 233,838 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 200 D $3.06 233,638 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 500 D $3.05 233,138 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 233,088 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 233,038 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 232,988 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 18 D $3.05 232,970 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 232,920 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.05 232,820 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 232,770 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.05 232,670 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.05 232,570 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 183 D $3.05 232,387 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 2 D $3.05 232,385 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 232,335 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 417 D $3.05 231,918 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 98 D $3.05 231,820 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 82 D $3.05 231,738 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 231,688 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.06 231,588 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 50 D $3.05 231,538 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.07 231,438 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 90 D $3.05 231,348 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 10 D $3.05 231,338 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.07 231,238 I See Footnotes(1)(2)(3)
Common Stock 02/02/2026 S 100 D $3.05 231,138 I See Footnotes(1)(2)(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
BANK OF AMERICA CORP /DE/
(Last) (First) (Middle)
BANK OF AMERICA CORPORATE CENTER
100 N TRYON ST
(Street)
CHARLOTTE NC 28255
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BOFA SECURITIES, INC.
(Last) (First) (Middle)
150 N COLLEGE ST
NC1-028-29-04
(Street)
CHARLOTTE NC 28255
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
BANK OF AMERICA NA
(Last) (First) (Middle)
100 NORTH TRYON STREET
(Street)
CHARLOTTE NC 28255
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. This statement is jointly filed by Bank of America, BANA and BOFAS. Bank of America holds an indirect interest in the securities listed in Table I ("the Securities") by virtue of its indirect ownership of its subsidiaries, BANA and BOFAS.
2. Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section13(d) of the US Securities Exchange Act of 1934 or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer of (ii) a member of any group with respect to the Issuer or any securities of the Issuer.
3. Without conceding its status as a greater than 10% beneficial owner or that the reported transactions are subject to disclosure under Section 16(a) of the Exchange Act or short-swing profit recovery under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that the Reporting Persons were greater than 10% beneficial owners and the transactions were subject to Section 16(b) has been or will be remitted to the Issuer.
Remarks:
Remaining trades included in attached schedule See Exhibit 99.2
BANK OF AMERICA CORP/DE/ By: Its: Authorized Signatory /s/ Andres Ortiz 02/04/2026
BOFA SECURITIES, INC. By: Its: Authorized Signatory /s/ Andres Ortiz 02/04/2026
BANK OF AMERICA NA By: Its: Authorized Signatory /s/ Andres Ortiz 02/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Bank of America report in ENvue Medical (FEED)?

Bank of America entities reported selling ENvue Medical common stock. Bank of America Corp, BOFA Securities and Bank of America NA jointly filed a Form 4 showing multiple open-market sales of ENvue Medical, Inc. common shares at prices just above $3 per share.

On what date did the ENvue Medical (FEED) insider sales by Bank of America occur?

The reported ENvue Medical sales occurred on 02/02/2026. All non-derivative transactions listed in the Form 4 are dated February 2, 2026, reflecting a series of same-day trades in ENvue Medical, Inc. common stock by entities affiliated with Bank of America.

At what prices were ENvue Medical (FEED) shares sold in this Form 4 filing?

The ENvue Medical shares were sold around $3.04–$3.07 per share. Individual trades in the Form 4 show sale prices including $3.04, $3.05, $3.06 and $3.07 for ENvue Medical, Inc. common stock, executed through multiple small transactions.

How many ENvue Medical (FEED) shares do the reporting persons hold after these sales?

The reporting persons show 231,138 ENvue Medical shares after the trades. The final line in Table I lists 231,138 ENvue Medical, Inc. common shares as beneficially owned following the reported transactions, held on an indirect basis by the Bank of America reporting group.

Who are the reporting entities in this ENvue Medical (FEED) Form 4?

The reporting entities are Bank of America Corp, BOFA Securities and Bank of America NA. The Form 4 is jointly filed, with a footnote explaining that Bank of America’s interest in the ENvue Medical common shares is held indirectly through its subsidiaries BANA and BOFAS.

What does the Form 4 say about short-swing profit recovery for ENvue Medical (FEED)?

The filing addresses potential short-swing profit recovery under Section 16(b). It states that any profit potentially recoverable by ENvue Medical, if the reporting persons were over 10% beneficial owners and subject to Section 16(b), has been or will be remitted to the issuer.

How is beneficial ownership characterized in the ENvue Medical (FEED) Form 4 footnotes?

The footnotes include disclaimers about beneficial ownership and group status. The reporting persons state they do not concede greater-than-10% beneficial ownership or group membership and emphasize that Bank of America’s interest in ENvue Medical, Inc. shares is held indirectly through its subsidiaries.